Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc

INTRODUCTION: Cenicriviroc (CVC), a once-daily, dual CCR5/CCR2 co-receptor antagonist, has completed Phase 2b development. CVC demonstrated favourable safety and similar efficacy compared with efavirenz (EFV) in Study 202 (NCT01338883); an ex vivo sub-analysis evaluated treatment effects on HIV entr...

Descripción completa

Detalles Bibliográficos
Autores principales: Kramer, Victor, Hassounah, Said, Colby-Germinario, Susan, Mesplède, Thibault, Lefebvre, Eric, Wainberg, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: International AIDS Society 2014
Materias:
Oral Presentation – Abstract O433
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224821/
https://www.ncbi.nlm.nih.gov/pubmed/25394040
http://dx.doi.org/10.7448/IAS.17.4.19531

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224821/
https://www.ncbi.nlm.nih.gov/pubmed/25394040
http://dx.doi.org/10.7448/IAS.17.4.19531

Ejemplares similares